SRZNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration...

Stats
本日の出来高	11 124.00
平均出来高	16 966.00
時価総額	28.72M
EPS	$0 ( 2024-04-03 )
次の収益日	( $-4.25 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.420
ATR14	$0.150 (1.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Li Yang	Buy	10 000	Option (right to buy)
2024-04-24	Li Yang	Buy	5 000	Restricted Stock Unit
2024-04-24	Parker Craig C	Buy	43 000	Option (right to buy)
2024-04-24	Williams Charles O	Buy	13 000	Option (right to buy)
2024-04-24	Williams Charles O	Buy	7 000	Restricted Stock Unit

INSIDER POWER
92.43
Last 99 transactions
Buy: 7 137 981 \| Sell: 808 309

Surrozen, Inc. 相関

10 最も正の相関
NXTC	0.94
PVBC	0.939
TOI	0.936
HHGCU	0.933
STSA	0.916
JNCE	0.916
PRVA	0.915
FAAR	0.909
VSTA	0.903
LPTX	0.9

10 最も負の相関
NRIM	-0.942
AMRB	-0.937
MDLZ	-0.928
CLRO	-0.928
LYLT	-0.923
STIM	-0.917
PBFS	-0.904
PRDO	-0.903
VLYPO	-0.901
LVHD	-0.901

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Surrozen, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-1.91M (0.00 %)
EPS:	$-21.33

FY	2023
収益:	$0
総利益:	$-1.91M (0.00 %)
EPS:	$-21.33

FY	2022
収益:	$12.50M
総利益:	$9.23M (73.85 %)
EPS:	$-11.95

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.556

Financial Reports:

No articles found.

Surrozen, Inc.

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.